Healthcare
GRAIL, Inc.(GRAL)
Live Price
Offline$63.74
+7.22% today
1Y Change
+29.53%
Window
Jun 25, 2025 β Jun 15, 2026
- Market Cap
- $2.19B
- Revenue Growth
- +17.2%
- EPS Growth
- +82.5%
- Dividend Yield
- 0.0%
Coverage: 244 bars Β· Jun 25, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GRAIL, Inc. (GRAL) is a Healthcare stock with a market cap of $2.19B and listed on NASDAQ. The stock last traded around $63.74 and up 29.5% across the available one-year price window (Jun 25, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of +17.2%, EPS growth of +82.5%, a dividend yield of 0.0%. What stands out right now is revenue +17.2%, EPS +82.5%, free cash flow +48.7% with operating margin -382.0% and ROIC -15.0%. Valuation already assumes a fairly strong business story at price/sales 14.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GRAL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.2% vs +7.6% peer median
Operating Margin
Below sector median
-382.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +17.2% and EPS at +82.5%, with operating margin around -382.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -13.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | β | -2.4% | -1.6% | -5.5% |
2026 Feb 19, 2026 | +26.7% | -50.5% | -42.8% | -52.3% |
2025 Nov 12, 2025 | +26.8% | -1.9% | +3.8% | +12.1% |
Benchmark Edge
GRAL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GRAL
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GRAL Max Drawdown
-62.92%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GRAL and SPY.
Company Overview
GRAIL, Inc.
NASDAQ Global Market
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
- Leadership
- Robert Ragusa
- IPO Date
- Jun 12, 2024
- Employees
- 1.0k
- Street Address
- 1525 OβBrien Drive
- Mailing
- Menlo Park, CA, 94025
- Region
- Menlo Park, CA, US
- Reporting Currency
- USD
- Investor Line
- 833-694-2553
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 14.9
- Price/Book
- 0.8
Growth
- Revenue
- +17.2%
- EPS
- +82.5%
- Free Cash Flow
- +48.7%
Profitability
- Gross Margin
- -42.5%
- Operating Margin
- -382.0%
- Net Margin
- -277.5%
- ROE
- -17.1%
- ROIC
- -15.0%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 11.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.